Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: The TREND (Trial on Reversing ENdothelial Dysfunction) study

Circulation

Volumn 94, Issue 3, 1996, Pages 258-265

  Mancini, G B John ^a,k   Henry, Gregory C ^b   Macaya, Carlos ^c   O'Neill, Blair J ^d   Pucillo, Anthony L ^e   Carere, Ronald G ^f   Wargovich, Thomas J ^g   Mudra, Harald ^h   Lüscher, Thomas F ⁱ   Klibaner, Michael I ^b   Haber, Harry E ^b   Uprichard, Andrew C G ^b   Pepine, Carl J ^g   Pitt, Bertram ^j  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PFIZER INC   (United States)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d DALHOUSIE UNIVERSITY   (Canada)

^e WESTCHESTER MEDICAL CENTER   (United States)

^f ST PAUL S HOSPITAL   (Canada)

^g UNIVERSITY OF FLORIDA   (United States)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j UNIVERSITY OF MICHIGAN   (United States)

^k VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

more..

Author keywords

acetylcholine; angiotensin; coronary disease; endothelium derived factors

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; GLYCERYL TRINITRATE; NITRIC OXIDE; QUINAPRIL; SUPEROXIDE;

ADULT; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; FEMALE; HEART CATHETERIZATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASOMOTOR REFLEX; VISUAL IMPAIRMENT;

EID: 9444280103     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.3.258     Document Type: Article

References (48)

1. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest. 1987;79:1-6.
2. Dzau VJ. Molecular and physiological aspects of tissue renin-angiotensin system: emphasis on cardiovascular control. J Hypertens. 1988;6(suppl 3):7S-12S.
3. Rubanyi GM, The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol. 1993;22(suppl 4):1S-14S.
4. Lüscher TF, Noll G. Endothelium dysfunction in the coronary circulation. J Cardiovasc Pharmacol. 1994;24(suppl 3):J6S-26S.
5. Vanhoutte PM. Endothelium and responsiveness of vascular smooth muscle. J Hypertens. 1987;5(suppl 5):115S-120S.
6. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323:27-36.
7. Zeiher AM, Schachinger V. Coronary endothelial vasodilator dysfunction: clinical relevance and therapeutic implications. Z Kardiol. 1994;83(suppl 3):7S-14S.
8. Henderson AH. Endothelium in control. Br Heart J. 1991;65:116-125.
9. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial Superoxide anion production. J Clin Invest. 1993;91:2546-2551.
10. Harrison DG. Endothelial dysfunction in atherosclerosis. Basic Res Cardiol. 1994;89(suppl 1):87-102.
11. Harrison DG, Ohara Y. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: implications for impaired vasomotion. Am J Cardiol. 1995:75:75B-81B.
12. Werns SW, Walton JA, Hsia HH, Nabel EG, Sanz ML, Pitt B. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation. 1989;79:287-291.
13. Cox DA, Vita JA, Treasure CB, Fish RD, Alexander RW, Ganz P, Selwyn AP. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation. 1989;80:458-465.
14. Egashira K, Inou T, Hirooka Y, Yamada A, Maruoka Y, Kai H, Sugimachi M, Suzuki S, Takeshita A. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest. 1993;91:29-37.
15. Becker RHA, Wiemer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol. 1991;18(suppl 2):S 110-5115.
16. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;15:327-331.
17. Powell JS, Clozel JP, Muller RKM, Kuhn H, Hefite F, Hosang M, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245:186-188.
18. Vanhoutte PM, Auch-Schwelk W, Biondi ML, Lorenz RR, Schini VB, Vidal MJ. Why are converting enzyme inhibitors vasodilators? Br J Clin Pharmacol. 1989;28:95S-104S.
19. Garavaglia GE, Messerli FH, Nunez BD, Schnieder RE, Frohlich ED. Immediate and short-term cardiovascular effects of a new converting enzyme inhibitor (lisinopril) in essential hypertension. Am J Cardiol. 1988;62:912-916.
20. Daemen MJAP, Lombardi DM, Bosnian FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68:450-456.
21. Naftilan AJ, Gilliland GK, Eldridge CS, Kraft AS. Induction of the proto-oncogene c-jun by angiotensin II. Mol Cell Biol. 1990;10:5536-5540.
22. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
23. Foris G, Dezso B, Medgyesi GA, Fust G. Effect of angiotensin II on macrophage functions. Immunology. 1983;48:529-535.
24. Chobanian AV. 1989 Corcoran lecture: adaptive and maladaptive responses of the arterial wall to hypertension. Hypertension. 1990;15:666-674.
25. Sharpe N. The effects of ACE inhibition on progression of atherosclerosis. J Cardiovasc Pharmacol. 1993;22(suppl 9):9S-12S.
26. Lüscher TF. Endothelium control of vascular tone and growth: potential role in coronary artery disease. In: Reiber JHC, Serruys PW, eds. Progress in Quantitative Coronary Arteriography. Doerdrecht, Netherlands: Kluwer Academic Press; 1994:3-18.
27. Dawkins R, Purcell TS. Investigator's brochure: quinapril hydrochloride (CI-906). Ann Arbor, MI: Parke-Davis; May 9, 1989.
28. Frank G, Knapp L, Phelps M, Quade M, Reiger M. Integrated summary of effectiveness of quinapril (section 8.E. of NDA 19-855). Ann Arbor, MI: Parke-Davis; Jan 26, 1989.
29. Johnston CI, Fabris B, Yamada H, Mendelsohn FAO, Cubela R, Sivell D, Jackson B. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens. 1989;7(suppl 5):11S-16S.
30. Fabris B, Yamada H, Cubela R, Jackson B, Mendelsohn FAO, Johnston CI. Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats. Br J Pharmacol. 1990;100:651-655.
31. Mancini GBJ, Simon SB, McGillem MJ, Lefree MT, Friedman HZ, Vogel RA. Automated quantitative coronary arteriography: morphologic and physiologic validation in vivo of a rapid digital angiographic method. Circulation. 1987;75:452-460.
32. Gibson CM, Sandor T, Stone PH, Pasternak RC, Rosner B, Sacks FM. Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. Am J Cardiol. 1992;69:1286-1290.
33. SAS Institute Inc. SAS Technical Report P-229: SAS/STAT Software-Changes and Enhancements. Cary, NC: SAS Institute; 1992:287-368. Release 6.07.
34. Brown MB. A test for the difference between two treatments in a continuous measure of outcome when there are dropouts. Control Clin Trials. 1992;13:213-225.
35. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
36. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
37. Haefeli WE, Linder L, Lüscher TF. Blockade of nitric oxide formation inhibits direct vasodilator effects of the ACE inhibitor quinaprilat. Circulation. 1994;90(pt 2):I-137. Abstract.
38. Yusuf S, Pepine CJ, Garces C, Pouler H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173-1178.
39. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.
40. Dohi Y, Hahn AWA, Boulanger CM, Bühler FR, Lüscher TF. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension. 1992; 19:131-137.
41. Lüscher TF, Boulanger CM, Dohi Y, Yang Z. Endothelium-derived contracting factors. Hypertension. 1992;19:117-130.
42. Chan DP, Kaiser J, Burnett JC Jr. The modulating effects of converting enzyme inhibition upon the intrarenal action of endothelin. Am J Hypertens. 1991;4:15A-16A. Abstract.
43. Kawaguchi H, Sawa H, Yasuda H. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J Mol Cell Cardiol. 1990;22:839-842.
44. Wiemer G, Scholkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium derived bradykinin. Hypertension. 1991;18:558-563.
45. Luskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb. 1989;9:87-115.
46. Rabbani LE, Loscalzo J. The effects of hyperlipidemia and atherosclerosis on endothelial function and vascular reactivity. Curr Opin Lipidol. 1991;2:259-265.
47. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90:2056-2069.
48. Texter M, Lees RS, Pitt B, Dinsmore RE, Uprichard ACG. The quinapril ischemic event trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention. Cardiovasc Drugs Ther. 1993;7;273-282.